| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H17Cl2F3N4O2 |
| Molar mass | 449.26 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
GW-842,166X is a drug which acts as a potent and selectivecannabinoidCB2receptoragonist, with a novel chemical structure based on apyrimidine core. It has potentanalgesic,anti-inflammatory andanti-hyperalgesic actions in animal models, but without cannabis-like behavioural effects due to its extremely low affinity for the CB1 receptor.[1][2] GSK brought this compound for into 4 clinical trials, two of them related to pain management[3][4] and the other two related to bio-distributions.[5][6] The trials were either withdrawn or completed without posting result.
Thiscannabinoid related article is astub. You can help Wikipedia byadding missing information. |